Nebenwirkungen · Gazyvaro
Gazyvaro 1 000 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-129946 · Präparat HOS-096817
The incidence of neutropenia was higher in the Gazyvaro plus chlorambucil arm (41%) compared to the rituximab plus chlorambucil arm with the neutropenia resolving spontaneously or with use of granulocyte-colony stimulating factors. The incidence of infection was 38% in the Gazyvaro plus chlorambucil arm and 37% in the rituximab plus chlorambucil arm (with Grade 3-5 events reported in 12% and 14%, respectively and fatal events reported in < 1% in both treatment arms). Cases of prolonged neutropenia (2% in the Gazyvaro plus chlorambucil arm and 4% in the rituximab plus chlorambucil arm) and late onset neutropenia (16% in the Gazyvaro plus chlorambucil arm and 12% in the rituximab plus chlorambucil arm) were also reported (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T10:49:00Z · SHA-256 18e252f824981860d284b6a8d0590c4e67726398fe4cfebbac1cb10441aeb96a · Passage 4d1423f1d52f984679f5a76be418d64ddd07988c2fe4a49697b3547554ed8b40 · Zeichen 15135–15882 im Abschnitt